Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

738
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
738

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor Microenvironment: Insights from Multiparametric MRI in Pancreatic Ductal Adenocarcinoma.

Cancers·2026
Same author

Of surrogate endpoints, shortcuts, and safety.

The Lancet. Oncology·2025
Same author

Differential Clearance of [<sup>177</sup>Lu]Lu-PSMA-617 from Metastatic Prostate Cancer Lesions and Normal Tissues creates a Window for Safe Application of DNA Repair Inhibitors.

medRxiv : the preprint server for health sciences·2025
Same author

Monte Carlo-based subcellular comparison of electron energy deposition by <sup>177</sup>Lu and <sup>161</sup> Tb: implications for targeted radiopharmaceutical therapy.

EJNMMI physics·2025
Same author

Apparent Diffusion Coefficient Magnetic Resonance Imaging as a Predictive Biomarker for Hypoxia, Treatment De-escalation, and Recurrence in Human Papillomavirus-Associated Oropharyngeal Cancer.

International journal of radiation oncology, biology, physics·2025
Same author

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: Mar 21, 2026

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

2.1K

Copper-64 trastuzumab PET imaging: a reproducibility study.

Jorge A Carrasquillo1,2, Patrick G Morris3,4, John L Humm5

  • 1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA - carrasj1@mskcc.org.

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of
|May 13, 2016
PubMed
Summary

ImmunoPET imaging with copper-64 (64Cu) trastuzumab is safe and reproducible for pharmacokinetic assessment. While feasible, tumor detection sensitivity was low when performed during trastuzumab therapy.

More Related Videos

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

9.3K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.4K

Related Experiment Videos

Last Updated: Mar 21, 2026

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
06:52

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

2.1K
Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

9.3K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

2.4K

Area of Science:

  • Nuclear Medicine
  • Radiopharmaceutical Imaging
  • Pharmacokinetics

Background:

  • Assessing the safety, pharmacokinetics, feasibility, and reproducibility of immunoPET imaging using copper-64 (64Cu) labeled trastuzumab.
  • Evaluating the potential of 64Cu-trastuzumab for imaging in patients undergoing trastuzumab therapy.

Purpose of the Study:

  • To evaluate the safety profile of 64Cu-trastuzumab immunoPET.
  • To determine the pharmacokinetic properties and reproducibility of 64Cu-trastuzumab imaging.
  • To assess the feasibility of using 64Cu-trastuzumab for tumor detection in the context of concurrent trastuzumab treatment.

Main Methods:

  • Administered intravenous 296-370 MBq/5 mg 64Cu-trastuzumab 1-4 hours post-routine trastuzumab dose.
  • Performed whole-body PET scans immediately and 24 hours post-injection, with serial pharmacokinetic assessments.
  • Eight of 11 patients (median age 52) underwent repeat studies to assess reproducibility; toxicity was monitored.

Main Results:

  • No allergic reactions or significant adverse effects were observed with 64Cu-trastuzumab.
  • Repeat studies demonstrated acceptable reproducibility in biodistribution and pharmacokinetic clearance (T1/2 ~45 hours).
  • Two patients showed 64Cu-trastuzumab localization in known tumor sites (liver, breast); sensitivity for tumor detection was low.

Conclusions:

  • 64Cu-trastuzumab immunoPET is feasible, safe, and reproducible for pharmacokinetic studies.
  • Observed tumor uptake suggests potential, but low sensitivity limits detection during concurrent trastuzumab therapy.